William Slikker

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

High Impact

Director

NCTR primary UAMS

Also affiliated: Northwestern University (2016); Rush University Medical Center (2012–2020); Boston Children's Hospital (2018); Environmental Protection Agency (2024); United States Food and Drug Administration (1980–2026); Center for Drug Evaluation and Research (2016); Harvard University (2018); Howard University (2024); University of British Columbia (1992); Medical University of South Carolina (2003); University of California, Santa Barbara (1976); University of California, Los Angeles (2004); University of Georgia (2024); University of Dundee (1983); Genentech (1992); University of Milan (2024); University of Arkansas Medical Center (1981); American Society for Surgery of the Hand (2016); Hospital for Sick Children (1997); University of Mississippi (1988); Office of the Director (2013); Charles River Laboratories (United States) (2024); Stanford Medicine (2011–2012); Connecticut Department of Public Health (2003); Kaiser Permanente San Leandro Medical Center (2021–2022); Health and Environmental Sciences Institute (2003); National Research Council Canada (1986); Rush University (2013–2014); University of Colorado Anschutz (2026); Arizona State University (2026); University of California, Davis (1981–2017); Stanford University (2011–2012); Mississippi State University (2024)

67 h-index 465 pubs 19,944 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website

OverviewAI-generated summary

William Slikker directs research focused on regulatory science, with a particular emphasis on toxicology and the application of emerging technologies. His work has explored the regulatory landscape of nanotechnology and nanoplastics from a global perspective, and the impact of new technologies on regulatory science frameworks. He has also investigated the intersection of artificial intelligence, real-world data, and public health, specifically in the context of drug and food safety.

Slikker's research extends to neuroprotection and neurotoxicity. He has studied the neurochemical effects of long-term methylphenidate treatment in nonhuman primates using microPET/CT imaging. His laboratory has also focused on establishing neural stem cells from fetal monkey brains for neurotoxicity testing and has investigated the neuroprotective potential of carnitine. His work also includes the transition from traditional animal models to New Approach Methodologies (NAMs) to protect human and animal health.

With an h-index of 67 and over 480 publications, Slikker is recognized as a highly cited researcher. His key collaborators include Tucker A. Patterson, Leah E. Latham, John Talpos, and Weida Tong, all from the National Center for Toxicological Research. He maintains an active laboratory website to disseminate his research.

Metrics

h-index: 67
Publications: 465
Citations: 19,944

Positions

Director 1978–present

NCTR/FDA Office of the Director ORCID
Director publications 1980–2026

National Center for Toxicological Research ORCID

Selected Publications

Emerging therapeutics and safety: Transdisciplinary science to address unique safety challenges of cannabis and psychedelics (2026)

DOI OpenAlex
Proposed key characteristics of neurotoxic chemicals (2025)

DOI OpenAlex
Realizing Impact of Artificial Intelligence in Real World Enhances Public Health (2025)

DOI OpenAlex
Biomarkers of Neurotoxicity and Disease (2025)

1 citation DOI OpenAlex
Protecting Human and Animal Health: The Road from Animal Models to New Approach Methods (2024)

Pharmacological Reviews 46 citations DOI OpenAlex
Integrating artificial intelligence with bioinformatics promotes public health (2023)

3 citations DOI OpenAlex
In pursuit of precision medicine for brain injury and neurotoxicity and improved protection of human health (2023)

DOI OpenAlex
Society for birth defects research and prevention's multidisciplinary research needs workshop 2022: A call to action (2023)

DOI OpenAlex
Establishment of neural stem cells from fetal monkey brain for neurotoxicity testing (2023)

3 citations DOI OpenAlex
Artificial intelligence and real-world data for drug and food safety – A regulatory science perspective (2023)

Regulatory Toxicology and Pharmacology 48 citations DOI OpenAlex
Discontinuation of methylphenidate after long-term exposure in nonhuman primates (2023)

3 citations DOI OpenAlex
Application of Nonhuman Primate Models in the Studies of Pediatric Anesthesia Neurotoxicity (2022)

5 citations DOI OpenAlex
Phencyclidine (PCP)-induced neurotoxicity and behavioral deficits (2022)

DOI OpenAlex
Analysis of biofluid lipid changes: potential biomarkers for detecting central nervous system diseases and neurotoxicity (2021)

2 citations DOI OpenAlex
MicroPET/CT assessment of neurochemical effects in the brain after long-term methylphenidate treatment in nonhuman primates (2021)

7 citations DOI OpenAlex